» Articles » PMID: 30392769

Long-term Follow-up of HIV-2-related AIDS and Mortality in Guinea-Bissau: a Prospective Open Cohort Study

Abstract

Background: HIV type 2 (HIV-2) is considered more benign and has fewer pathogenic consequences than HIV type 1 (HIV-1) for most infected individuals. However, reliable estimates of time to AIDS and mortality among those with HIV-2 infection are absent. We therefore aimed to compare the time to AIDS and mortality, and the CD4 T-cell dynamics between those infected with HIV-1 and HIV-2.

Methods: We did a prospective open cohort study. We included all police officers with regular employment from police stations in both urban and rural areas of Guinea-Bissau since Feb 6, 1990. We continued to include participants until Sept 28, 2009, and follow-up of HIV-1-positive and HIV-2-positive individuals continued until Sept 28, 2013. We collected blood samples at enrolment and at scheduled annual follow-up visits at police stations. We analysed longitudinal data from individuals infected with HIV-1 and HIV-2 according to time to AIDS, time to death, and T-cell dynamics. Time of HIV infection was estimated as the mid-timepoint between last HIV-seronegative and first HIV-seropositive sample. Data from an additional 2984 HIV-uninfected individuals from the same population were analysed to assess the effect of natural mortality on HIV-related mortality.

Findings: 872 participants tested HIV positive during the 23-year study period: 408 were infected with HIV-1 (183 infected before and 225 infected after enrolment) and 464 were infected with HIV-2 (377 before and 87 after enrolment). The median time from HIV infection to development of AIDS was 6·2 years (95% CI 5·4-7·1) for HIV-1 infection and 14·3 years (10·7-18·0) for HIV-2 infection (p<0·0001). The median survival time after HIV infection was 8·2 years (95% CI 7·5-8·9) for HIV-1 infection and 15·6 years (12·0-19·2) for HIV-2 infection (p<0·0001). Individuals who were infected with HIV-1 or HIV-2 before enrolment showed similar results. Comparison with uninfected individuals indicated limited confounding contribution from natural mortality. Mean CD4 percentages were higher in individuals with HIV-2 than in those with HIV-1 during early infection (28·0% [SE 1·3] vs 22·3% [1·7]; p=0·00094) and declined at a slower rate (0·4% [0·2] vs 0·9% [0·2] per year; p=0·028). HIV-2-infected individuals developed clinical AIDS at higher mean CD4 percentages (18·2%, IQR 7·2-25·4) than HIV-1-infected individuals (8·2%, 3·0-13·8; p<0·0001).

Interpretation: Our results show that both HIV-1-infected and HIV-2-infected individuals have a high probability of developing and dying from AIDS without antiretroviral treatment.

Funding: Swedish International Development Agency, Swedish Research Council, Swedish Society of Medical Research, Medical Faculty at Lund University, and Region Skåne Research and Development.

Citing Articles

Extra-Cavitary Primary Effusion Lymphoma in a Patient Co-infected With HIV-1 and HIV-2: A Case Review.

Miguel M, Robalo Nunes T, Gomes A, Boavida S, Marques N Cureus. 2025; 16(12):e75039.

PMID: 39749085 PMC: 11694847. DOI: 10.7759/cureus.75039.


Novel Dolutegravir and Lenacapavir Resistance Patterns in Human Immunodeficiency Virus Type 2 Infection: A Case Report.

van Kampen J, van Nood E, Mahmud R, Krullaars Z, Voskamp T, Voskamp M Open Forum Infect Dis. 2025; 12(1):ofae705.

PMID: 39741997 PMC: 11685954. DOI: 10.1093/ofid/ofae705.


Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2.

Kiarie I, Hoffka G, Laporte M, Leyssen P, Neyts J, Tozser J Viruses. 2024; 16(10).

PMID: 39459940 PMC: 11512360. DOI: 10.3390/v16101607.


HIV-2 mediated effects on target and bystander cells induce plasma proteome remodeling.

Johansson E, Nazziwa J, Freyhult E, Hong M, Lindman J, Neptin M iScience. 2024; 27(4):109344.

PMID: 38500818 PMC: 10945182. DOI: 10.1016/j.isci.2024.109344.


Genotypic and Phenotypic Characterization of Replication-Competent HIV-2 Isolated from Controllers and Progressors.

Lungu C, Overmars R, Grundeken E, Boers P, van der Ende M, Mesplede T Viruses. 2023; 15(11).

PMID: 38005913 PMC: 10675771. DOI: 10.3390/v15112236.